|
|
Pluristem’s PLX Cells May
Effectively Treat Ischemic Stroke - Brain Research Journal Reports
More ...
|
|
|
Pluristem Therapeutics
Announces Interim Results from PLX-PAD Clinical Trials
Data Suggests PLX-PAD is Safe and Potentially Efficacious
More ...
|
|
2009 Press Releases |
|
|
Data Safety Monitoring
Board (DSMB) Approves Advancement to Intermediate Dose Level of PLX-PAD
More ...
|
|
|
Pluristem Will Present on
the Value of Placental-derived Mesenchymal Stromal Cells in Wound
Healing at the 10th Annual Wound Healing: Science and Industry
Conference
More ...
|
|
|
Pluristem Therapeutics Will
Present on Clinical Trial Standardization and Overcoming Regulatory
Hurdles at the 7th Annual Commercial Translation of Regenerative
Medicine
More ...
|
|
|
Pluristem Therapeutics
Completes Dosing of First Group of Patients in Europe with
Placenta-Derived Cell Therapy Product PLX-PAD in Phase I Clinical
Trial for Treatment of Critical Limb Ischemia (CLI)
More ...
|
|
|
Pluristem Therapeutics
Presents Three Month Follow-Up Data from First Patient to Receive
Placental Derived PLX-PAD at Two Meetings in Germany and France
Presentations also Address the Strategic
Partnerships in the Life Science Industry and the Development of PLX
Cells for the Treatment of Intestinal Disease
More ...
|
|
|
Pluristem Therapeutics
Announces Three Month Follow-Up Data from the First Patient to
Receive PLX-PAD
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured
Efficacy Parameters
More ...
|
|
|
Pluristem Therapeutics Will
Present on Clinical Trial Agreements at the Clinical Trial Magnifier
Conference
More ...
|
|
|
Pluristem Therapeutics Will
Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at
the World Conference on Regenerative Medicine
More ...
|
|
|
Pluristem Therapeutics Will
Present at the New England-Israel Life Sciences Summit
More ...
|
|
|
Pluristem Therapeutics to
Raise $3.0 Million in Registered Direct Offering
More ...
|
|
|
Pluristem Therapeutics Has
Been Selected to Present at The Israeli Presidential Conference
2009: Facing Tomorrow, Based on the Company’s Proprietary Technology
and the Potential to Shape The Future of the Stem Cell Industry
More ...
|
|
|
Pluristem Therapeutics
Doses First Patient in U.S. With Placenta-Derived Stem Cell Product
PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral
Artery Disease
More ...
|
|
|
Pluristem Begins Enrollment
in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in
a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
More ...
|
|
|
Pluristem Therapeutics Will
Present its Unique Placenta Derived Stem Cell Therapy Approach at
Charles River Biotech Symposium
More ...
|
|
|
Pluristem Therapeutics Will
Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at
MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference
More ...
|
|
|
Pluristem’s Award from the
Israeli Office of the Chief Scientist Increased to $2.3 Million
More ...
|
|
|
Griffin Securities
Initiates Independent Research Coverage on Pluristem Therapeutics
Inc.
More ...
|
|
|
Pluristem Therapeutics
Announces First Patient Enrollment in Phase I Clinical Trial for
Treatment of Peripheral Artery Disease With PLX-PAD
More ...
|
|
|
Pluristem Therapeutics was
Awarded a $1.9 Million Grant from the Office of the Chief Scientist
in the Israeli Government
More ...
|
|
|
Pluristem Therapeutics
Receives European Regulatory Approval for Placental-Derived Stem
Cell Clinical Trial
Approval Paves Way for US and European Trials That
Will Enroll Patients Diagnosed with Critical Limb Ischemia Who are
Facing Amputation
More ...
|
|
|
Pluristem Therapeutics to
Present at the Second Annual Life Science Conference of The Society
of Investment Professionals in Germany
More ...
|
|
|
Pluristem Therapeutics to
Present at the 8th Israel Life Science Industry (ILSI) BioMed
Conference
More ...
|
|
|
Stanford's Professor John
Cooke Joins Pluristem's Scientific Advisory Board
More ...
|
|
|
Pluristem Therapeutics to
Present at the International Society for Stem Cell Research (ISSCR)
7th Annual Meeting
More ...
|
|
|
Pluristem Therapeutics to
Present at the Center for Finance Education
More ...
|
|
|
Pluristem Therapeutics
Announces $1.3 Million Securities Offering with Two Institutional
Investors
Healthcare fund to subscribe to the majority of the
offering
More ...
|
|
|
Pluristem Therapeutics
Announces Major Clinical Site in North Carolina for PLX-PAD Phase-I
Trial
More ...
|
|
|
Pluristem Therapeutics to
Present at the 2009 BIO International Convention as Part of the
Israeli Delegation
More ...
|
|
|
Pluristem Therapeutics to
Present Its Clinical Path at the International Society for Cellular
Therapy (ISCT) 15th Annual Meeting
More ...
|
|
|
Pluristem Therapeutics to
Present at the Tel-Aviv Stock Exchange
More ...
|
|
|
Pluristem Therapeutics to
Sponsor the World Conference on Regenerative Medicine
More ...
|
|
|
Pluristem Therapeutics to
Present at the German Equity Forum
More ...
|
|
|
Pluristem Therapeutics to
Present at “The Stem Cell Network” Conference
More ...
|
|
|
Pluristem Therapeutics
Prepares for Placental-Derived Stem Cell Clinical Trial
More ...
|
|
|
Pluristem Therapeutics
Receives FDA Clearance to Begin “First-In-Human” Placenta-Derived
Stem Cell Clinical Trial
More ...
|
|
|
Pluristem Therapeutics Collaborates with Pharmicell Europe GmbH to
Distribute Pluristem's Cell Therapy Product for Clinical Trials in
Germany
More ...
|
|
|
Pluristem Therapeutics to Present at Italian CREM Workshop Focused on
Placental-Derived Cells
More ...
|
|
|
Pluristem Therapeutics Appoints Dr. Frida Grynspan to Vice President
of Research and Development
More ...
|
|
|
Pluristem Receives Deficiency and Compliance Notice from Nasdaq.
Company is Now in Compliance
More ...
|
|
|
Pluristem Therapeutics’ cGMP Facilities Approved for Clinical
Manufacturing in Europe
More ...
|
|
|
Pluristem Therapeutics Announces US $1,200,000 Restricted Share
Purchase
More ...
|
|
|
Pluristem Therapeutics Collaborates with the Charité -
Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for
its Clinical Trials in Germany
More ...
|
|
|
Pluristem Therapeutics to Present at the 19th Israeli Medical
Association World Fellowship International Conference
More ...
|
|
|
Pluristem Therapeutics Files an IND Application with the FDA to
Initiate a Phase I Clinical Trial Utilizing PLX-PAD for Critical
Limb Ischemia
More ...
|
| 2008
Press Releases |
|
|
Pluristem Therapeutics Inc. Announces Filing an
IMPD to Commence Clinical Trials Utilizing PLX-PAD
for Critical Limb Ischemia in Europe
More ...
|
|
|
Pluristem Receives $1.6M Grant from the Office of Israel's Chief
Scientist
More ...
|
|
|
Pluristem Therapeutics Announces US$ 600,000 Restricted Share
Purchase.
Management and Board of Directors Invested Additional $150,000 in
the Company
More ...
|
|
|
Pluristem Retains KKS as Its CRO for Upcoming Limb
Ischemia Clinical Trial
More ...
|
|
|
Pluristem Therapeutics Inc. to Present its Clinical
Plan at the Rodman & Renshaw 10th Annual Healthcare Conference
More ...
|
|
|
Pluristem Announces its Appointment to the Advisory
Board of The Stem Cell Partnering Series
More ...
|
|
|
Pluristem Therapeutics Announces US$1
Million Sale of Shares at 44% Premium to Market Price
More ...
|
|
|
Pluristem Presents Final PLX-PAD Efficacy Data
Supporting Upcoming IND Submission to the U.S. FDA
More ...
|
|
|
Pluristem Therapeutics to Present at the bioLOGIC
Conference
More ...
|
|
|
Pluristem Successfully Concludes Final Pre-Clinical
Safety Studies with PLX-PAD in Preparation for Human Trials
More ...
|
|
|
Pluristem Therapeutics to Present at the
Noble Financial Equity Conference
More ...
|
|
|
Pluristem's PLX-MS Shows Potential Benefit
in the Prevention of Multiple Sclerosis
More ...
|
|
|
Pluristem Therapeutics Announces $1.6 Million
Securities Offering
More ...
|
|
|
Pluristem Appoints Ms. Chaya Mazouz
Clinical Operations Director
More ...
|
|
|
The Esteemed Dr. Brian Annex Accepts
Pluristem's Invitation to Join its Scientific Advisory Board
More ...
|
|
|
Pluristem's PLX-BMT Product Featured in the Journal
''Expert Opinion on Biological Therapy''
More ...
|
|
|
Pluristem Certified as a Good Manufacturing Practices
(GMP) Site for the Manufacture of PLX cells for its Clinical Trials
More ...
|
|
|
Pluristem's President & CEO to be Keynote Speaker at
The 4th Annual Stem Cells Asia Congress
More ...
|
|
|
Pluristem to Exhibit and Present at the BIO
International Convention
More ...
|
|
|
Pluristem Demonstrates the Potential of Its
PLX Cells to Treat Crohn's Disease and Ulcerative Colitis
More ...
|
|
|
Pluristem to Present at Rodman & Renshaw
5th Annual Global Healthcare Conference
More ...
|
|
|
Pluristem to be Featured on RedChip's Real
Radio(TM) Show Broadcast
More ...
|
|
|
Pluristem Announces Removal of Restrictive
Legends on Shares of Restricted Common Stock According to May 2007
Private Placement Agreement
More ...
|
|
|
FDA and the Paul Ehrlich Institute
(Germany) Approve Pluristem's Regulatory Submissions in Support of a
Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery
Disease
More ...
|
|
|
Pluristem to Present at LD MICRO Conference
April 29, 2008
 More ...
|
|
|
Pluristem to Present to President Bush and Others at
the First Annual Israeli Presidential Conference
More ...
|
| |
Dutton Associates Announces Investment Opinion:
Pluristem Life Sciences Maintained At Speculative Buy By Dutton
Associates
More ...
|
| |
Pluristem's PLX Cells Show a Statistically Significant
Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model
More ...
|
| |
Pluristem's Second Pre-Clinical Study in Ischemic
Stroke Shows Statistically Significant Advantages in Functional and
Anatomical Recovery
More ...
|
| |
Pluristem Submits Pre-IND Application in Germany to
Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
More ...
|
| |
Dutton Associates Announces Investment Opinion: Pluristem Therapeutics
Rated Speculative Buy in Update Report by Dutton Associates
More ...
|
| |
Pluristem Announces Second Clinical Indication Revascularization
Effect After PLX-PAD Therapy
More ...
|
| 2007
Press Releases |
|
|
Pluristem to Present at the Annual Meeting of the American Society of
Hematology PLX-BMT Promotes the Engraftment of Human Umbilical Cord
Blood Cells in Animals
More ...
|
|
|
Pluristem's Proprietary PLX Cells Demonstrate Promising Potential in
Treating Autoimmune Disorders
More ...
|
|
|
Pluristem's Reverse Stock Split Effective Today Stock to Trade Under
the New Symbol PSTI
More ...
|
|
|
CORRECTING and REPLACING Pluristem Completes Construction of Its New
GMP Facilities to Support Production for Clinical Trials
More ...
|
|
|
IPluristem Announces a Reverse Stock Split in Conjunction With Its
Application for Listing on the NASDAQ Capital Market
More ...
|
|
|
Independent Study by Fraunhofer Institute in Germany, Using
Pluristem's PLX Cells, Shows Promise in the Treatment of Ischemic
Stroke More ...
|
|
|
Pluristem Life Systems to Present at the Noble Financial Two
Double-0-Seven Small Cap Equity Conference More ...
|
|
|
Pluristem Life Systems to Present at the Noble Financial Two
Double-0-Seven Small Cap Equity Conference More ...
|
|
|
Pluristem's PLX Cells Show Promise in Treating Limb Ischemia More ...
|
|
|
Former CEO of US Bioscience, Inc., Dr. Philip J. Schein, Joins
Pluristem Business Advisory Board More ...
|
|
|
Pluristem and Center for Regenerative Therapies at Charite
University Hospital of Berlin Enters into Collaborative Research Agreement More ...
|
|
|
Pluristem Life Systems Hires American Capital Ventures to Provide Investor
Relations Services
More ...
|
|
|
Pluristem's PLX Cells
Demonstrate Potential to Treat Parkinson's Disease
More ...
|
|
|
Frank Carlucci to Chair
Pluristem Life Systems, Inc. Strategic Business Advisory Board
More ...
|
|
|
Pluristem Receives $830,000
Grant from Israeli Government for Development of the PLX-BMT Stem Cell
Product
More ...
|
|
|
Pluristem Acquires Patents
and Technology for the Three Dimensional Expansion of Human Cells
More ...
|
|
|
Pluristem Closes on $13.5
Million Private Equity Investment
More ...
|
|
|
Pluristem Shares Commence
Trading on Frankfurt Stock Exchange
More ...
|
|
|
Pluristem to Present Two
Scientific Posters at the International Society for Cellular Therapy
More ...
|
|
|
Pluristem Life Systems,
Inc. Retains Strategic Growth as a Global Investor Relations Advisor
More ...
|
|
|
Dr. William R. Prather,
Senior VP of Corporate Development, is the Featured Guest in an
Audio Interview at SmallCapVoice.com
More ...
|
|
|
Pluristem Life Systems,
Inc. Receives $1.1 Million From Exercise of Warrants
More ...
|
|
|
Pluristem Upgrading Its
Manufacturing Facility to Support $200 Million in Production
Capacity for PLX - I
More ...
|
|
|
Pluristem Announces Scientific Advance in Stem Cell Research; Evidence That PLX Cells Are Immunosuppressive.
More ...
|
|
|
Pluristem Life Systems,
Inc. Announces First Licensing Agreement and Stock Swap With Stem
Cell Innovations, Inc.
More ...
|
|
|
Pluristem Announces Private Equity Investment of $8M
More ...
|
|
|
Pluristem
Announces US FDA Acceptance of its Pre-IND Application to begin
Pre-clinical Studies using PLX- I in Hematological Malignancies
More ...
|
|
|
Pluristem
Announces Evidence That PLX-BMT Cells Are Immune Privileged
More ...
|
|
|
Pluristem
Appoints Dr. William R. Prather as Senior VP of Corporate
Development
More ...
|
|
|
Pluristem
Submits Pre-Investigational New Drug Document to FDA.
More ...
|
| 2006
Press Releases |
|
Pluristem
to Present at Annual Meeting of American Society of Hematology:
Breakthrough Method Improves Engraftment of Umbilical Cord Blood in
Treating Severe Blood Disorders.
More ...
|
|
Pluristem
Appoints Yaky Yanay Chief Financial Officer.
More ...
|
|
Pluristem
Expects to Submit Pre-IND Document to FDA by End of 2006
More ...
|
|
Pluristem
Completes Conversion of Outstanding Convertible Debentures.
More ...
|
|
Pluristem
Upgrades Manufacturing Facilities to Enable Production of First
Biological Product for Phase I Clinical Trials
More ...
|
|
Pluristem
Pre-Clinical Results: Placenta Expanded Cell Therapy Product
Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow
Transplants.
More ...
|
|
Pluristem Selected to Present at International Society
for Experimental Hematology Meeting More ...
|
|
Pluristem to Present at Biotech & Life Sciences Global
Venture Congress in New York City More ...
|
|
Pluristem Receives $470,000 Grant from Israeli
Government to Further Develop PLX-BMT Stem Cell Product More ...
|
|
Pluristem Life Systems CEO Featured in Exclusive
Interview With WallSt.net More ...
|
|
Pluristem Announces Breakthrough in Bone Marrow
Transplants: Engrafted Cells Increase 2-4 Times in Preclinical Study More ...
|
|
Pluristem Life Systems Retains Biologics Consulting
Group to Pursue FDA Approval of PLX-1 More ...
|
|
Pluristem Life Systems Engages Emerson Gerard
Associates to Mount Media Relations Campaign More ...
|
|
Pluristem Appoints Dr. Edwin Horwitz to Scientific
Advisory Board More ...
|
|
Pluristem Files Patent Application For PLX-1, Intended
as an Innovative Stem Cell Solution For Improved Engraftment During
Bone Marrow Transplantation
More ...
|
|
Pluristem Initiates Pre-Clinical Study for PLX-1, an Innovative Stem
Cell Solution for Improved Engraftment During Bone Marrow
Transplantation
More ...
|
|
Pluristem Announces Closing of 7% Senior Secured Convertible Debenture
Private Placement
More ...
|
|
Pluristem Strengthens Business Strategy Company to Focus on
Commercializing Cell Therapy Products
More ...
|
|
Pluristem Files Patent Application For Expanding Hematopoeitic Stem
Cells (HSC) and Early Progenitor Cells from Cord Blood Non Selected
Mono-Nuclear Cells (MNC)
More ...
|
 |
|
Pluristem Announces Advanced Engineered Cell Graft to Improve
Resurgence of the Hematopoietic Stem Cells in Bone Marrow for Cancer
Patients
More ...
|
| 2005
Press Releases |
|
Pluristem Ignites Technological Innovation in the Selection and
Separation of Hematopoetic Stem Cells from Cord Blood for Bone
Marrow Transplantation .
More ...
|
|
|
Pluristem Appoits Arnon Nagler, M.D., MSc. to Scientific Advisory
Board
More ...
|
|
|
Pluristem Appoints Dr. Ora Adout-Burger Vice
President of Development
More ...
|
|
|
Pluristem Announces Joint Projects Product Development and Worldwide
Distributorship Agreement with Biological Industries, Ltd.
More ...
|
|
|
Pluristem Obtains Issuance from U.S. Patent Office for Coverage of
Proprietary Stem Cell Expansion Technology .
More ...
|
|
|
Pluristem Board Appoints Zami Aberman as Chief Executive Officer
More ...
|
|
|
Pluristem Obtains Notice of Allowance from U.S. Patent Office
Providing Broad Coverage of Proprietary Stem Cell Expansion
Technology
More ...
|
|
|
Pluristem Completes $3.2 Million Interim Private Placement
More ...
|
|
|
Pluristem Ignites Technological Innovation in the Selection and
Separation of Hematopoetic Stem Cells from Cord Blood for Bone
Marrow Transplantation .
More ...
|
|
|
Pluristem Consummates $755,000 Interim Private Placement
More ...
|
| 2004
Press Releases |
|
Pluristem Founder Dr. Shai Meretzki Takes Helm as Acting CEO .
More ...
|
|
|
Pluristem Retains Stem Cell Leader Dr. Avraham -- Avi -- Treves to Consult On Development of Its Products and Technology.
More ...
|
|
|
Pluristem and the Technion -- Israel Institute of Technology Awarded ``Magneton'', Grant from Office of the Chief Scientist .
More ...
|
|
|
Pluristem Chosen To Present At The International Society for Experimental Hematology Annual Meeting -- New Orleans, July 2004.
More ...
|
|
|
Pluristem Announces Appointment of Dr. Menachem -- Mendi -- Ze'evi As Chief Executive Officer
More ...
|
|
|
PLURISTEM LIFE SYSTEMS INC Files SEC form 10QSB, Quarterly Report.
More ...
|
|
|
Pluristem CEO Conducts Live Webcast to Provide Current Status and Forward Momentum
More ...
|
|
|
Pluristem To Present at the 10th Annual Meeting of the International Society for Cellular Therapy -- ISCT --, Dublin, Ireland
More ...
|
|
|
Pluristem to Commence Animal Model Studies Utilizing Proprietary Stem Cell Expansion Technology
More ...
|
|
|
PPluristem Achieves Milestone in Cord Blood Stem Cell Expansion for Transplantation Using its Proprietary PluriX/TM/ Bioreactor System
More ...
|
|
|
Pluristem Announces the Appointment of Prof. Tsvee Lapidot from the Weizmann Institute of Science as Scientific Advisor for Analyzing Pluristem Expansion Technology
More ...
|
|
|
Webcast Alert: Pluristem Life Sciences Presentation at Informed Investors Biotechnology Stocks Virtual Forum to be Webcast on Tuesday, March 9, 2004, 10:00 am ET
More ...
|
|
